Trial results

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

NCT05254314 on ClinicalTrials.gov · last registry update 2026-06-24

Closed to new participants; the 100 already enrolled are still being followed. Due to report September 2026, alongside 37 other tracked readouts that quarter. Primary outcome, as filed: The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 11 October 2022 — 3 years so far.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Vanderbilt University Medical Center

Sponsor type

Other

Enrollment

100

Started

2022-10-11

Primary completion

2026-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity.

Conditions studied

Asthma

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.